Skip Navigation



Human Molecular Genetics Advance Access [Accepted Manuscript] published online on October 20, 2009

Human Molecular Genetics, doi:10.1093/hmg/ddp484
This Article
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Reichman, S.
Right arrow Articles by Léveillard, T.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reichman, S.
Right arrow Articles by Léveillard, T.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

THE HOMEOBOX GENE CHX10/VSX2 REGULATES RDCVF PROMOTER ACTIVITY IN THE INNER RETINA

Sacha Reichman1, Ravi Kiran Reddy Kalathur2, Sophie Lambard1, Najate Ait-Ali1, Yanjiang Yang3, Aurélie Lardenois2, Raymond Ripp2, Olivier Poch2, Donald J. Zack1,3, José-Alain Sahel1 and Thierry Léveillard1,*

1 Department of Genetics, Institut de la Vision, INSERMT Université Pierre et Marie Curie-Paris6, UMR-S 968, Paris, F-75012 France, 2 Institut de Génétique et de Biologie Moléculaire et Cellulaire T (TIGBMC), T67404 Illkirch CEDEXT France, 3 Wilmer Ophthalmological Institute, Johns Hopkins University School of Medicine, 600 N. Wolfe St.T TBaltimore,T MD 21287 USA

* Corresponding author: Thierry Léveillard, Department of Genetics, Institut de la Vision, INSERM, UPMC Univ Paris 06, UMR-S 968, CNRS 7210, Paris, F-75012 France. Tel : 33 1 53 46 25 48, Fax : 33 1 53 46 25 02, Email : thierry.leveillard{at}inserm.fr

Received September 30, 2009; Revised October 18, 2009; Accepted October 18, 2009

Rod-derived Cone Viability Factor (RdCVF) is a trophic factor with therapeutic potential for the treatment of retinitis pigmentosa, a retinal disease that commonly results in blindness. RdCVF is encoded by Nucleoredoxin-like 1 (Nxnl1), a gene homologous with the family of thioredoxins that participate in the defense against oxidative stress. RdCVF expression is lost after rod degeneration in the first phase of retinitis pigmentosa, and this loss has been implicated in the more clinically significant secondary cone degeneration that often occurs. Here we describe a study of the Nxnl1 promoter using an approach that combines promoter and transcriptomic analysis. By transfection of selected candidate transcription factors, chosen based upon their expression pattern, we identified the homeodomain proteins CHX10/VSX2, VSX1, and PAX4, as well as the zinc finger protein SP3, as factors that can stimulate both the mouse and human Nxnl1 promoter. In addition, CHX10/VSX2 binds to the Nxnl1 promoter in vivo. Since CHX10/VSX2 is expressed predominantly in the inner retina, this finding motivated us to demonstrate that RdCVF is expressed in the inner as well as the outer retina. Interestingly, the loss of rods in the rd1 mouse, a model of retinitis pigmentosa, is associated with decreased expression of RdCVF by inner retinal cells as well as by rods. Based upon these results, we propose an alternative therapeutic strategy aimed at recapitulating RdCVF expression in the inner retina, where cell loss is not significant, to prevent secondary cone death and central vision loss in patients suffering from retinitis pigmentosa.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.